Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis

Plain-language summary

This study examined the effectiveness of transplanting laboratory-expanded, bone marrow-derived allogeneic mesenchymal stem cells in patients with liver cirrhosis due to Wilson's disease. The cells were given through the portal vein, hepatic artery or a peripheral vein, and the study enrolled patients with liver involvement. It was conducted as a trial with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Murat Kantarcioglu

Intervention

allogeneic mesenchymal stem cell transplantation

Start date

4/1/2011

Estimated completion

12/1/2014

Countries

Turkey (Türkiye)

Related genes

Locations

• Ankara, Turkey (Türkiye)

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Clinical, radiologic and pathologically proven Wilson's Disease with hepatic presentation
* Patients with no hepatic malignancies
* No co-existing serious respiratory and/or cardiovascular morbidities
* Patients who approved to join the study group with informed and written consent
* Patients with platelet count more than 30.000/mm3

Exclusion Criteria:

* Clinical diagnosis of Wilson's Disease with neuropsychiatric presentation
* Current alcohol consumption
* Patients who have acute or chronic viral hepatitis infection